The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans (NCT06972407)
๐ฉบ Plain-English Summary (8th-Grade Level)
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. Common genetic variation in the TCF7L2 locus (T-allele at rs7903146) arguably confers the greatest genetic risk of T2DM. It is associated with ฮฑ- and ฮฒ-cell dysfunction. TCF7L2 (the product of TCF7L2) was first described as the transcription factor necessary for proglucagon expression in intestinal L-cells (which secrete GLP-1). This led to speculation that TCF7L2 confers risk of diabetes via changes in circulating GLP-1. This has turned out to not be the case. This raises the possibility that these diabetogenic effects are mediated via an inability of islet GLP-1 to adapt to rising glycemia. Therefore, this experiment will determine the contribution of islet GLP-1 to the functional abnormalities of the islet associated with the TCF7L2 locus.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic in Rochester โ Rochester, Minnesota
Age range: 25 Years to 70 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- Mayo Clinic in Rochester โ Rochester, Minnesota
๐ Contact the Study Coordinator
Phone: (507) 255-6515
Email: vella.adrian@mayo.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Genetic Predisposition
- Genetic Investigation of Cancer Predisposition โ San Antonio, Texas
- APOL1 Genetic Testing in African Americans โ St Louis, Missouri
- Barriers and Facilitators of Parent-Child Communication in Children With Cancer Predisposition โ Memphis, Tennessee
- GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH โ Boston, Massachusetts
- Using the EHR to Advance Genomic Medicine Across a Diverse Health System โ Philadelphia, Pennsylvania
Explore by condition: All Genetic Predisposition clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.